On October 11th to 13th, “The 6th China Big Health Industry Upgrading Summit” was held in Chengdu. The topics covered  market environment, investment hotspots and industry transformation of seven major sectors including digital healthcare, AI/algorithm-driven new drug design,  intelligent elderly care, etc. The “2021 Winner  List of Top Integrated Innovation Companies in China Big Health Industry” was announced. NeoCura is honored as “China TOP10 Innovative AI/Algorithm Biopharma  Company for 2021” by virtue of its outstanding performance in advancing research and development of RNA innovative drugs through AI technologies.

With new technologies emerging, medical sub-sectors keep pushing boundaries, which presents the trend of integration and brand-new perspectives. During the interactive integration and development of medical industries, innovative forces have emerged in large numbers. The “China TOP10 Innovative AI/Algorithm Biopharma  Companies 2021” list aims to identify the most innovative and vibrant AI biopharma companies in China, demonstrate the value of AI-driven drug  innovation, and build up ecological network, thus promoting the innovation and development of new industries.

In this year's appraisal, the panel of judges adhered to the principles of fairness and impartiality and referred to the hard indicators such as the company’s foundation time, financing rounds, and operation performance as well as the soft factors such as company's field  prospect, project innovation, product differentiation and brand awareness. After multiple rounds of appraisal, 10 outstanding AI-driven innovative biopharma  companies were selected. NeoCura is honored in this list as a rising star in the field of AI-driven RNA new drug development, which shows the industry's high recognition for NeoCura’s comprehensive strength.

At present, the exploration and application of AI in drug development  have been continuously expanding, and the increasing maturity of artificial intelligence has boosted the development of innovative drugs significantly. At the “AI/Algorithm -Driven New Drug Development Industry Forum”, the guests had carried out in-depth exchanges about “How AI and Algorithm Drive New Drug Development”.

Dr. Wang Yi, Founder and CEO of NeoCura, said that, “As a high-tech company that uses AI to energize development of RNA innovative drugs, NeoCura mainly uses AI for deep drug target mining and fully automated drug design. NeoCura has conducted in-depth research in tumor treatment, and is currently accelerating the iteration of innovative technology platforms, accumulation of standardized massive data and commercialization of R&D findings. In the short term, AI can effectively reduce R&D costs and greatly improve the efficiency and accuracy of target screening. In the future, we will continue to unleash the potential of AI and protect  life and health.”

NeoCura is committed to building  global leading RNA innovative drug platform. It has independently developed the AI bioinformatic target mining platform, , fully automated drug design platform, multi-omics big data collection and analysis platform, drug discovery & validation platform and RNA drug delivery platform. These five scientific platforms jointly promote RNA drug research. The ALPINE cancer neoantigen prediction platform, which is independently developed by NeoCura with sole ownership, has the highest accuracy of neoantigen prediction in the world.

With a long way to go, NeoCura will keep driving technological innovations to accelerate pipeline research and development and providing patients with revolutionary treatment regimens through intellectual anti-cancer technologies.